Strategic partnerships Leverage ANT's exclusive Cleveland Clinic license and FDA Breakthrough Designation to approach cardiovascular device manufacturers and vascular intervention teams for co-development, licensing, or integration deals around SirPlux Duo or future dual-drug delivery platforms.

Clinical pipeline Target large interventional cardiology and peripheral vascular disease stakeholders with opportunities in in-stent restenosis, small-vessel coronary interventions, and below-the-knee disease, emphasizing the potential for improved lesion-targeting and sustained tissue retention.

Funding momentum Capitalize on recent Series B financing to propose scale-up collaborations, joint ventures, or named pilots with strategic investors and hospital networks seeking validated, high-impact medical devices in high-need vascular markets.

Regulatory readiness Position SirPlux Duo as a near-market candidate by aligning with regulatory affairs teams to explore accelerated pathways, pivotal study planning, and real-world evidence programs that can de-risk adoption by payers and providers.

Clinical economics Highlight potential cost-savings and outcome improvements from dual-drug delivery, targeting hospital systems and device manufacturers interested in reducing restenosis rates, shortening procedures, and improving long-term durability to drive adoption and procurement.